Proteasome inhibitor bortezomib modulates TLR4-induced dendritic cell activation
Alessio Nencioni(Ospedale Policlinico San Martino), Peter Brossart(University of Bonn)
Cited by 132
Related Papers
Differential impact of allelic ratio and insertion site in FLT3-ITD–positive AML with respect to allogeneic transplantation
|Blood|2014|400
Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use
|Clinical Cancer Research|2019|160